191 related articles for article (PubMed ID: 17396141)
1. Standardization of HER2 testing: results of an international proficiency-testing ring study.
Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
3. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
4. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
[TBL] [Abstract][Full Text] [Related]
6. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
7. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study.
Md Pauzi SH; Masir N; Yahaya A; Mohammed F; Tizen Laim NMS; Mustangin M; Aizudin AN; Talib A; Teoh KH; Karim N; Oy-Leng JW; Rajadurai P
Indian J Pathol Microbiol; 2021; 64(4):677-682. PubMed ID: 34673585
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
13. Maximizing the response to Herceptin therapy through optimal use and patient selection.
Leyland-Jones B
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S11-7. PubMed ID: 11989522
[TBL] [Abstract][Full Text] [Related]
14. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
[TBL] [Abstract][Full Text] [Related]
15. Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.
Bianchi S; Caini S; Paglierani M; Saieva C; Vezzosi V; Baroni G; Simoni A; Palli D;
Pathol Oncol Res; 2015 Apr; 21(2):477-85. PubMed ID: 25367072
[TBL] [Abstract][Full Text] [Related]
16. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
17. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
[TBL] [Abstract][Full Text] [Related]
19. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
20. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
